Generic name: Triamcinolone acetonide extended-release
Depostiva is a novel, extended-release, microsphere-based formulation of triamcinolone acetonide (TA) embedded in a biodegradable poly lactic-co-glycolic acid (PLGA) matrix.
After intra-articular injection of Depostiva, biodegradation of PLGA microspheres begins with the formation of small channels on their surface. These small channels allow slow drug release and extend residence time of triamcinolone acetonide (TA) in the synovial fluid up to 12 weeks.
Mechanism of Action
Triamcinolone acetonide is a corticosteroid with anti-inflammatory and immunomodulating properties. It binds to and activates the glucocorticoid receptor, leading to activation of anti-inflammatory transcription factors and inhibition of inflammatory transduction pathways.
Management of osteoarthritis pain of the knee
Dosage form and strength
Intra-articular injectable suspension that delivers 32 mg of triamcinolone acetonide supplied as a single-dose kit containing one vial of Depostiva microsphere powder and one vial of 5 mL diluent.
Intra-articular injection only